AI MARKET SCANNING

Nkarta Inc

📅 Next Catalyst: Nov 10, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP +0.44%
MAX GAP RECORD -22.96%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $NKTX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 10, 2026 Earnings Release 2026-11-10 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 10, 2026 Earnings Release 2026-08-10 (AFTER CLOSE)
-4.88%
Mar 25, 2026 Earnings Release 2026-03-25 (AFTER CLOSE)
+0.00%
Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE)
+0.00%
Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE)
+2.04%
May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE)
-4.81%
Mar 26, 2025 Earnings Release 2025-03-26 (AFTER CLOSE)
+11.68%
Nov 07, 2024 Earnings Release 2024-11-07 (AFTER CLOSE)
+0.61%

VOLATILITY & GAP BIAS

AVG GAP MOVE 6.1%
Bullish Gaps (5)
Bearish Gaps (4)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $NKTX

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗